

15th International Workshop on Multiple Endocrine Neoplasia and other rare endocrine tumors



PROGRAM BOOK

September 29 - October 1, 2016
Utrecht, THE NETHERLANDS



Program at a glance

Thursday, September 29

- 11:30 – 17:30 Registration desk open
- 12:15 – 13:45 Sponsored symposium, with lunch (see page 36)
- 12:15 – 13:45 Young investigators meeting (expedition)
- 14:15 – 16:00 Welcome and opening
- 16:00 – 16:30 Coffee break, exhibition
- 16:30 – 17:30 Hereditary primary hyperparathyroidism
- 18:00 – 20:00 Opening Reception University Hall,
including complimentary drinks and snacks
(see page 8)

Friday, September 30

- 08:00 – 18:30 Registration desk open
- 08:30 – 10:00 Metastasized NET
- 10:00 – 10:30 Coffee break, exhibition
- 10:30 – 11:30 HOT topics session
- 11:30 – 12:30 DpNet (gastrinoma and pNET)
- 12:30 – 13:30 Lunch, exhibition
- 13:30 – 14:30 Quality of life in patient with MEN1
- 13:30 – 14:30 Basic science oral presentations
- 14:30 – 15:30 Poster Session
- 15:30 – 16:00 Coffee break, exhibition and poster viewing
- 16:00 – 17:15 State of the art: pituitary
- 17:15 – 18:15 Molecular mechanisms of hereditary tumor syndromes
- 17:15 – 18:15 Clinical oral presentations
- 19:15 Symposium drinks and dinner - ticketed (see page 8)

Saturday, October 1

- 08:00 – 18:30 Registration desk open
- 08:30 – 09:50 MEN2/ hereditary paraganglioma
- 09:50 – 10:50 Clinical oral presentations
- 09:50 – 10:50 Basic oral presentations
- 10:50 – 11:20 Coffee break, exhibition
- 11:20 – 12:20 Back to the future - interactive discussions
- 12:20 – 13:00 Awards and farewell

For the detailed program by day and session, see the next pages.
The numbers shown next to lecture starting times represent abstract
numbers. You will find abstracts on www.worldmen2016.org.

Scientific programme per day

Thursday, September 29

Plenary hall		Expedition	
12:15 13:45	Symposium IPSEN (with lunch): Where NET meets MEN, 2016 Chairs: Prof. G. D. Valk and Prof. M. R. Vriens, UMC Utrecht, Utrecht, The Netherlands	12:15 14:00	Young investigators meeting Chairs: Drs. R. van Leeuwen and Drs. C. Pieterman, UMC Utrecht, Utrecht, The Netherlands
12:15 12:20	Introduction by the chairs	12:15 12:25	Introduction by chair
12:20 12:45	K1.1 What's new in the ENETS guidelines 2016? Prof. P. Ruszniewski, University of Paris VII, Beaujon Hospital, Paris, France	12:25 13:00	3 minute pitch by all participants
12:45 13:10	K1.2 The bridge between MEN and NET Prof. M. Timmers, UMC Utrecht, Utrecht, The Netherlands	13:00 13:25	K14.1 How to set up an international research network Prof. M. Brandi, University of Florence, Florence, Italy
13:10 13:40	K1.3 Neuroendocrine tumor case discussions Dr. C. Toumpanakis, Royal Free London NHS Foundation Trust, London, United Kingdom	13:25 13:45	Working in small groups on how to initiate an international collaboration in your field of interest.
13:40 13:45	Closure	13:45 14:00	Plenary discussion on international collaboration

Thursday, September 29

Plenary hall		Expedition	
14:15 16:00	Welcome and opening Chairs: Prof. G. D. Valk and Prof. M. R. Vriens, UMC Utrecht, Utrecht, The Netherlands		
14:15 14:30	Opening		
14:30 15:00	K2.1 What's hot: MEN1 Prof. R. Thakker, Oxford Centre for Diabetes, Oxford, United Kingdom		
15:00 15:30	K2.2 What's hot: MEN2/ MTC Dr. B. Havekes, Maastricht UMC+, Maastricht, The Netherlands		
15:30 16:00	K2.3 What's hot: hereditary pheochromocytomas and para-gangliomas Prof. K. Pacak, National Institutes of Health, Bethesda, MD, United States		
		16:00 - 16:30 Break / Transit	
16:30 17:30	Hereditary primary hyperparathyroidism Chair: Prof. I. Borel Rinkes, UMC Utrecht, Utrecht The Netherlands		
16:30 17:00	K3.1 Diagnosis and medical treatment Prof. M. Brandi, University of Florence, Florence, Italy		
17:00 17:30	K3.2 Surgical therapy Dr. M. Iacobone, University of Padua, Padua, Italy		
		18:00 - 20:00 Opening Reception University Hall	

Progress

8:30 10:00	Metastized NET Chair: Dr. B. Havekes, Maastricht UMC+, Maastricht, The Netherlands
8:30 8:50	K4.1 Metastized NET - diagnosis and radiological treatment Prof. M. Lam, UMC Utrecht, Utrecht, The Netherlands
8:50 9:15	K4.4 The Clinical Utility of Multianalyte algorithmic analysis of circulating gene transcripts in neuroendocrine tumor management Prof. I. Modlin, Yale University, New Haven, CT, United States
9:15 9:35	K4.2 Metastized NET - medical treatment Dr. M. Tesselaa, Antoni van Leeuwenhoek, Amsterdam, The Netherlands
9:35 10:00	K4.3 Metastized NET - surgical treatment Dr. P. Goudet, CHU Dijon Bourgogne, Dijon, France

10:00 - 10:30 Coffee Break / Transit

10:30 11:30	HOT topics session Chair: Prof. A. Hermus, Radboud UMC, Nijmegen, The Netherlands
10:30 10:45	O1.1 Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: relevance to Hyperparathyroidism-Jaw Tumour Syndrome Dr. M. Stevenson, University of Oxford, Oxford, United Kingdom

09:00
|
10:00
General Assembly EMENA
Chair: Ms. P. Bruegmann, Netzwerk Endokrinologie, Furlh, Germany

Patients and Nurses Symposium
Chairs: Mr. N. van der Meij and Drs. C. Pieterman, UMC Utrecht, Utrecht, The Netherlands

K9.1 Guiding patient with a genetic disease
Dr. M. McAllister, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom

Friday, September 30

Progress		Mission 1		Expedition	
10:45 11:00	01.2 Parathyroid-Specific Deletion Of Cdc73/Hrpt2 In Mice Results In Hypo-parathyroidism <i>Dr. J. Costa-Guda, UConn Health Center, Farmington, CT, United States</i>			11:00 11:30	K9.2 Nuclear medicine in diagnosis and therapy <i>Dr. J. Teunissen, Erasmus Medical Centre, Rotterdam, The Netherlands</i>
11:00 11:15	01.3 Total versus subtotal and less than subtotal parathyroidectomy in men 1: outcome and complications <i>Drs. T. Cavalli, University of Florence, Florence, Italy</i>			11:30 12:00	K9.3 Care for patients treated with somatostatin analogues <i>Ms. W. Geilvoet, Erasmus Medical Center, Rotterdam, The Netherlands</i>
11:15 11:30	01.4 Prevalence of chronic kidney disease and the effect of parathyroid-ectomy on kidney function in patients with multiple endocrine neoplasia type-1 <i>Dr. N. Nilubol, National Institutes of Health, Bethesda, MD, United States</i>			12:00 12:30	K9.4 Care for patients treated with targeted therapy <i>Ms. L. Saveur, Antoni van Leeuwenhoek, Amsterdam, The Netherlands</i>
11:30 12:30	dpNET (gastrinoma and pNET) <i>Chair: Dr. E. Nieveen van Dijkum, AMC, Amsterdam, The Netherlands</i>				
11:30- 12:00	K5.1 Diagnosis/surveillance <i>Dr. F. Wessels, UMC Utrecht, Utrecht, The Netherlands</i>				
12:00- 12:30	K5.2 Treatment <i>Prof. D. Bartsch, Philipps University Marburg, Marburg, Germany</i>				
12:30 - 13:30 Lunch / Transit					
13:30 14:30	Quality of live in patient with MEN1 <i>Chair: Dr. A. van der Horst, UMCG, Groningen, The Netherlands</i>	13:30 14:30			
13:30 13:50	K6.1 From patient's perspective <i>Mrs. P. Vlasblom-Dorgelo, Belangengroep M.E.N., Utrecht, The Netherlands</i>	13:30 13:40			02.1 Tissue specificity of MEN1-related pancreatic neuroendocrine tumors <i>Dr. S. Agarwal, National Institutes of Health, Bethesda, MD, United States</i>

Mission 1

Progress

13:50 14:10	K6.2 QoL in MEN1 - the Dutch cohort Drs. R. van Leeuwen, UMC Utrecht, Utrecht, The Netherlands
14:10 14:30	K6.3 QoL in MEN1 - the USA cohort Dr. C. Sturgeon, Northwestern University, Chicago, IL, United States
13:40 13:50	02.2 The epigenetic modifier (+)-JQ1 inhibits proliferation and increases apoptosis of pancreatic neuroendocrine tumours (PNETs) in vitro and in vivo Dr. K. Lines, University of Oxford, Oxford, United Kingdom
13:50 14:00	02.3 Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas Dr. F. Marini, University of Florence, Florence, Italy
14:00 14:10	02.4 Clinical impact of multiple ligation-dependent probe amplification (MLPA) in investigation of gross deletions of the MEN1 gene Prof. D. Lourenço Jr, University of São Paulo School of Medicine, São Paulo, Brazil
14:10 14:20	02.5 ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma Dr. D. Iacovazzo, Barts and The London School of Medicine, London, United Kingdom
14:20 14:30	06.4 Inherited and sporadic medullary thyroid carcinoma (MTC): experience from the administration of tyrosine kinase inhibitors (TKI) in progressive disease Prof. Alevizaki, Athens University School of Medicine, Athens, Greece

Friday, September 30

Progress		Mission 1		Expedition	
16:00 17:15		State of the art: pituitary Chair: Prof. A. Pereira, Leiden University Medical Center, Leiden, The Netherlands		Patient and Nurses Symposium Chairs: Mr. N. van der Meij and Drs. C. Pieterman, UMC Utrecht, Utrecht, The Netherlands	
				K7.1 Genetic pituitary tumors - clinical Prof. A. Beckers, Centre Hospitalier Universitaire de Liège, Liège, Belgium	
16:00 16:20		K7.2 Therapy - surgical Dr. W. van Furth, Leiden University Medical Center, Leiden, The Netherlands		K10.2 Introduction in VHL and Hereditary paraganglioma's Dr. K. Dreijerink, UMC Utrecht, Utrecht, The Netherlands	
16:20 16:40		K7.3 Genetic pituitary tumors - research Prof. C. Stratakis, National Institutes of Health, Bethesda, MD, United States		K11.1 Your wish is our command. Introduction: from research to practice; followed by interactive part: what do patients want in research Prof. O. Dekkers, Leiden University Medical Center, Leiden, The Netherlands	
16:40 17:00		Discussion		K12.1 Oncological rehabilitation Drs. G. Hesselmann, UMC Utrecht, Utrecht, The Netherlands	
17:00-17:15					
14:30-15:30 Poster Sessions / Transit					
15:30 - 16:00 Break with poster viewing / Transit					

Friday, September 30

Progress		Mission 1		Expedition	
17:15 18:15	Molecular mechanisms of hereditary tumor syndromes Chair: Prof. M. Timmers, UMC Utrecht, Utrecht, The Netherlands	17:15 18:15	Clinical oral presentations Chair: Dr. P. Bisschop, AMC, Amsterdam, The Netherlands	17:15 17:45	K12.2 News in treatment MEN2a/MEN2b Dr. B. Havekes, Maastricht UMC+, Maastricht, The Netherlands
17:15 17:30	03.1 Enhancer-mediated function of Menin Dr. K. Dreijerink, UMC Utrecht, Utrecht, The Netherlands	17:20 17:30	04.1 Pheochromocytoma in MEN2: Changes in mode of diagnostic and therapeutic management during the last 4 decades Prof. F. Raue, Endocrine Practice, Heidelberg, Germany		
17:30 17:45	03.2 Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas Dr. R. Toledo, CNIO, Madrid, Spain	17:30 17:40	04.2 Is screening of young asymptomatic MEN1 patients necessary? Dr. J. Manoharan, University of Marburg, Marburg, Germany		
17:45 18:00	03.3 Genotype-phenotype Correlation in Patients with Germline Mutations of VHL, RET, SDHB and SDHD Genes: Thai Experience Dr. C. Sriphrapradang, Mahidol University, Bangkok, Thailand	17:40 17:50	04.3 Distribution of RET mutations in MEN2 in Denmark 1994-2014: a nationwide study Dr. J. Mathiesen, Odense University Hospital, Odense, Denmark	17:45 18:15	K12.3 Children and MEN syndrome Ms. J. Grey, CEO AMEND, Kent, United Kingdom
18:00 18:15	03.4 Hereditary and somatic RET proto-oncogene mutations in Polish population -comprehensive study based on two decades of referral center experience Dr. M. Oczko-Wojciechowska, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland	17:50 18:00	04.4 Clinicopathological features and biological behavior in pancreatic neuroendocrine tumors. Differences between familial and sporadic tumors Dr. J. Rodriguez, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain		
		18:00 18:10	02.6 The current treatment for primary hyperparathyroidism in MEN1 in Japan: the analysis of data from MEN Consortium of Japan Dr. K. Horiuchi, Tokyo Women's Medical University, Tokyo, Japan		

19:15 Conference drinks and dinner

Saturday, October 1

Mission 1

Progress

8:30
|
9:50
MEN2/ hereditary paraganglioma
Chair: Prof. M. Drent, VU MC, Amsterdam, The Netherlands

8:30
|
9:00
K8.1 MTC: surgical strategies
Prof. N. Perrier, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

9:00
|
9:30
K8.2 Metastatic MTC: medical therapy
Dr. J. de Boer, Antoni van Leeuwenhoek, Amsterdam, The Netherlands

9:30
|
9:50
K8.3 Pheochromocytoma/paraganglioma: imaging
Dr. H. Timmers, Radboud UMC, Nijmegen, The Netherlands

9:50
|
10:50
Clinical oral presentations
Chair: Prof. A. Hermus, Radboud MC, Nijmegen, The Netherlands

9:55
|
10:05
05.1 Management of MEN1 related NF-PNETs: a shifting paradigm. Results from the DutchMEN1 Study Group
Drs. S. Nell, UMC Utrecht, Utrecht, The Netherlands

10:05
|
10:15
05.2 Optimal age to start screening for breast cancer in women with MEN1
Drs. R. van Leeuwen, UMC Utrecht, Utrecht, The Netherlands

Expedition

8:30
|
10:50
Patient and Nurses Symposium
Chairs: Mr. N. van der Meij and Drs. C. Pieterman, UMC Utrecht, Utrecht, The Netherlands

8:30
|
9:15
K13.1 Advocacy groups in different countries
Ms. C. Kleinegris, President Stichting NET-groep, Hoofddorp, The Netherlands
Ms. P. Bruegmann, Netzwerk glandula, Fürth, Germany; Ms. J. Grey, CEO Amend, Kent, United Kingdom; Drs. C. Pieterman, Secretary European MEN Association (EMENA), Utrecht, The Netherlands

9:15
|
9:45
K13.2 News in treatment MEN1
Prof. R. Thakker, Oxford Centre for Diabetes, Oxford, United Kingdom

9:45
|
10:15
K13.3 MEN syndrome and hypocortisolism
Mr. N. van der Meij, UMC Utrecht, Utrecht, The Netherlands

9:50
|
10:50
Basic oral presentations
Chair: Prof. M. Iacobone, University of Padua, Padua, Italy

9:55
|
10:05
06.1 A missense mutation in the islet-enriched transcription factor MAFA leads to familial insulinomatosis and diabetes mellitus
Dr. D. Iacovazzo, Barts and The London School of Medicine, London, United Kingdom

10:05
|
10:15
06.2 A rare germline Leu63Pro missense mutation in CDC73 resulting in hyperparathyroidism jaw-tumour syndrome with variable phenotype
Mr. T. Cvasciuc, Leeds Teaching Hospital, Leeds, United Kingdom

Saturday, October 1

Progress		Mission 1		Expedition	
10:15 10:25	05.3 Description of known and unknown manifestations of Carney Complex based on the French national prospective study Eva-Carney Presenter: Prof. J. Bertherat, Assistance Publique Hôpitaux de Paris, Paris, France Author: Dr. S. Espiard, CHR-U de Lille, Lille, France	10:15 10:25	06.3 Familial primary hyperparathyroidism in young patients in Russia identified by next-generation sequencing Dr. E. Mamedova, Endocrinology Research Center, Moscow, Russia	10:15 10:45	K13.4 Plain summary of conference highlights Drs. C. Pieterman, UMC Utrecht, Utrecht, The Netherlands
10:25 10:35	05.4 Late onset of euparathyroidism after total parathyroidectomy with autograft in MEN1 Dr. M. Brescia, University of São Paulo School of Medicine, São Paulo, Brazil	10:25 10:35	04.5 Genetic heterogeneity of Medullary Thyroid Carcinoma Drs. C. Romei, University of Pisa, Pisa, Italy		
10:35 10:45	05.5 Can Precision Medicine be done with Surgical Precision: Prophylactic Thyroidectomy in Children with MEN2 in United Kingdom Mr. T. Kurzawinski, University College London Hospital, London, United Kingdom	10:35 10:45	06.5 Revealing an unclassified 611 variant of the RET proto-oncogene as a disease-causing mutation Dr. B. Lapauw, Ghent University Hospital, Ghent, Belgium		
10:50 - 11:20 Coffee Break / Transit					
11:20 12:20	Back to the future - interactive discussions Chairs: Prof. G. D. Valk and Prof. M. R. Vriens, UMC Utrecht, Utrecht, The Netherlands				
11:20 11:50	Future: care interactive discussion				
11:50 12:20	Future: research (collaboration)				
12:20 13:00	Awards and farewell				